Boltz raises $110M after 50-fold surge in AI usage

London-based Boltz has raised $110 million (€100 million) in a Series A led by Bessemer Venture Partners to expand its AI platform for designing small-molecule drugs and therapeutic proteins. The financing comes as the company reports rapidly growing adoption among major pharmaceutical companies.

ADVERTISEMENT

Unlike AI drug discovery companies building their own pipelines, Boltz is positioning itself as a technology provider. Its business model is to give pharmaceutical and biotech researchers access to advanced molecular design models, allowing them to explore potential drug candidates before committing to expensive laboratory experiments.

Backstory: Founded in 2025 by researchers from the Massachusetts Institute of Technology (MIT), Boltz initially gained attention for its open-source AI models, including Boltz-1 and Boltz-2, which predict molecular structures, interactions and binding affinities. The company’s founders include CEO Gabriele Corso, Chief Technology Officer Jeremy Wohlwend and Saro Passaro, who leads research.

How it works: Boltz has since expanded into molecular generation with two proprietary models launched in June:

  • BoltzMol-1 identifies and designs small molecules that could bind to specific biological targets. In experiments reported in June, the company identified confirmed hits against six of 10 challenging targets, testing just 28 to 51 compounds per target.
  • BoltzProt-1 designs proteins, including antibody-like binders, that recognize selected targets.

These models are available through Boltz Lab, a platform that allows scientists to run computational experiments, and through an API that can be integrated into existing research workflows. Boltz says it has signed partnerships with six of the world’s 20 largest pharmaceutical companies, including Pfizer, GSK, Takeda and Bristol Myers Squibb.

Rather than charging for individual drug discovery programs, Boltz sells computational capacity through molecular tokens, units measuring the molecular information processed by its AI models. This allows customers to pay according to their usage. The company reported that the volume of molecular tokens processed for paying customers has increased 50-fold since June, following the launch of its proprietary models.

The financing: Bessemer Venture Partners led the round, with existing investors Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures participating. New backers include Greycroft, F-Prime Capital, Hummingbird and Benchling.

The financing follows a $28 million seed round unveiled in January, bringing Boltz’s disclosed funding to $138 million in less than a year.

The big picture: Boltz is betting that AI-powered molecular design will become a routine part of drug discovery, much like computational chemistry or sequencing analysis. The company says its models have already been used by more than 100,000 scientists, while its team has grown to about 40 researchers and engineers.

Boltz’s financing comes just a day after fellow London-based AI biotech Isomorphic Labs raised a staggering $5 billion Series C, one of the largest private biotech funding rounds ever. While the two companies are pursuing different business models, the announcements underline investors’ growing willingness to commit substantial capital to AI-powered drug discovery.

What’s next: Boltz plans to invest the new capital in computing infrastructure, data, model development and recruitment. Its long-term ambition is to enable scientists to progress from a therapeutic hypothesis to a molecule ready for human testing entirely through computational design. Achieving that goal remains a substantial scientific challenge.

YOU DON`T WANT TO MISS ANYTHING?

Sign up for our newsletter!